Impaired antioxidant HDL function is closely associated with clinically relevant AKI outcomes. nHDLox, therefore, represents a significant risk factor in both cardiovascular and kidney disease.
Pagonas et al. (Tue,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: